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Labour induction at term - a randomised trial comparing 
Foley catheter plus titrated oral misoprostol solution, titrated 
oral misoprostol solution alone, and dinoprostone 
Baron B Matonhodze, G Justus Hofmeyr, Jonathan Levin 
Objectives. To compare three methods of labour induction. 
Design. Randomised controlled trial. 
Setting. Academic hospitals in Johannesburg, South Africa. 
Subjects. Women with intact membranes due for induction of 
labour. 
Method. Randomised, sealed opaque envelopes were used to 
allocate women to labour induction with extra-amniotic Foley 
catheter/titrated oral misoprostol solution (N = 174), titrated 
oral misoprostol solution alone (N = 176), or vaginal 
dinoprostone (N = 176). Misoprostol was dissolved in water 
and 20 - 40 g was given 2-hourly. 
Outcome measures. These were failure to deliver vaginally 
within 24 hours, additional measures for induction or 
augmentation of labour, analgesia, and maternal and fetal 
complications. 
Mechanical methods (catheters or hygroscopic dilators 
introduced into the extra-amniotic space via the cervical canal) 
were among the first methods of cervical ripening and labour 
induction developed.1 Potential advantages include simplicity 
of use, low cost and few side-effects. Despite the availability of 
pharmacological methods over recent decades, the Foley 
catheter2 and the 'Atad' double balloon catheter' are still in use, 
with or without the injection of saline solution or 
prostaglandins into the extra-amniotic space.' In a systematic 
review of 45 randomised trials, mechanical methods of labour 
induction were found to be less effective than prostaglandins 
and reduced the risk of uterine hyperstimulation; compared 
with oxytocin, there were fewer caesarean sections with 
mechanical methods.5 A recent small studt found that the 
combination of an extra-amniotic Foley catheter with vaginal 
misoprostol was not significantly more effective than 
misoprostol alone, although there was a trend to fewer cases of 
tachysystole. 
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Results. In the Foley catheter group, misoprostol was required 
in all but 1 case. Failure to deliver vaginally within 24 hours 
was similar for the three groups (79/174 v. 70/176 v. 70/176 
respectively). Labour augmentation, caesarean section and 
instrumental delivery were used somewhat more frequently 
in the Foley /misoprostol group than in the misoprostol alone 
group, but these differences were not statistically significant. 
More analgesia was used in the Foley catheter/misoprostol 
group than in the misoprostol group (64/172 v. 46/175). Side-
effects and neonatal complications were similar for the three 
groups. 
Conclusions. Use of extra-amniotic Foley catheter placement 
showed no measurable benefits over the use of oral 
misoprostol alone, or vaginal dinoprostone. 
S Afr Med J 2003; 93: 375-379. 
Prostaglandin E2 (PGE2) is regarded as the 'gold standard' 
for labour induction, but is unaffordable in many resource-poor 
settings. 
Misoprostol is a unique prostaglandin E1 analogue that has 
found wide application in clinical medicine including cervical 
ripening and labour induction.'-11 One of the major problems 
has been finding the ideal dose to minimise its side-effects, 
particularly uterine hyperstimulation. Several cases of uterine 
rupture have also been reported.12 Following completion of a 
small dose-finding pilot study/' we developed a novel 
approach to the use of misoprostol for labour induction, 
administering 20 - 40 g of misoprostol solution orally every 2 
hours, titrated against the uterine response. This new method 
was compared with conventional labour induction using 
vaginal dinoprostone in a multicentre trial in Johannesburg 
and Liverpool.14 Because it may be difficult to eliminate uterine 
hyperstimulation completely with this method, we also 
investigated the effectiveness of a mechanical method (Foley's 
catheter) followed when necessary by oral misoprostol 
titration. A randomised study design was used, nested within liiJ 
the larger trial. Those women with intact membranes enrolled 
at the South African sites were randomly allocated to Foley 
catheter I oral misoprostol, oral misoprostol alone or vaginal 




Eligible women with clinical indications for labour induction at 
or after 34 weeks' gestation and intact membranes were 
recruited into the study at Coronation Women's and Children's 
Hospital and at Chris Hani Baragwanath Hospital in 
Johannesburg. The study protocol was approved by the 
Committee for Research on Human Subjects of the University 
of the Witwatersrand. Signed and informed consent was 
obtained from each participant and baseline demographic 
details were completed. Exclusion criteria were: uterine scar, 
uncontrolled medical complications such as diabetes mellitus 
and severe hypertension, non-vertex presentations, multiple 
pregnancy, fetal distress and antepartum haemorrhage. 
Baseline cardiotocography was performed to rule out fetal 
compromise, followed by a cervical score assessment. A 
modified Bishop's score of< 7 was classified as unfavourable.15 
Membrane status was noted. The next in a series of opaque, 
sealed and numbered treatment envelopes in computer-
generated random sequence was taken out of one of four 
dispensers for: intact membranes/unfavourable cervix, intact 
membranes/favourable cervix, ruptured 
membranes/unfavourable cervix and ruptured 
membranes/favourable cervix. The first two categories 
reflected the tJ;uee-way randomisation reported here. 
Management followed the protocol indicated in the envelope 
unless clinical imperatives dictated otherwise. Analysis was by 
'intention to treat', The protocols were as follows: 
Foley catheter/titrated oral misoprostol solution 
The cervix was visualised using a sterile bivalved vaginal 
speculum. An 18 - 20-gauge Foley catheter with a 30 ml bulb 
was passed through the cervix, and the bulb inflated with 50 
ml sterile saline or water. The speculum was removed and the 
catheter taped to the woman's slightly flexed leg with light 
traction. If the bulb did not fall out within 24 hours it was 
deflated and removed. If, after removal or spontaneous 
expulsion of the catheter, labour contractions had not 
con:menced, titrated oral misoprostol solution was started. A 
200 p.g misoprostol tablet was dissolved in 200 ml tap water in 
a medicine bottle and shaken before use. Twenty ml (= 20 p.g), 
increasing to 40 ml after three doses, was taken orally every 2 
hours until active labour (three contractions per 10 minutes, 
with each contraction lasting 30 seconds or more). If after 
established labour the contractions became inadequate, 
augmentation with misoprostol solution (5 p.g hourly, 
increasing if necessary to 10 and 20 p.g) was used. If the 
clinician judged that misoprostol augmentation was ineffective, 
standard oxytocin augmentation was used. 
Titrated oral misoprostol 
Titrated oral misoprostol solution was used as described above. 
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Conventional method (dinoprostone) 
Dinoprostone gel 2 mg was inserted into the posterior vaginal 
fornix, and repeated after 6 hours if the patient was not in 
established labour. If not in active labour after 12 hours, 
oxytocin infusion was commenced, starting at 2 miU (6 drops) 
per minute and increased every 20 minutes until adequate 
contractions occurred. Labour was augmented with oxytocin if 
contractions became inadequate. 
If hypersystole (more than five contractions per 10 minutes 
for at least 20 minutes) or hypertonus (a contraction lasting at 
least 2 minutes) occurred, the woman was placed in the left 
lateral position with continuous fetal heart rate monitoring. If 
there were accompanying fetal heart rate abnormalities, oxygen 
was administered using a face mask, and 5- 10 p.g 
hexoprenaline was administered intravenously over 5- 10 
minutes. 
Routine artificial rupture of membranes to augment labour 
was discouraged in all three groups because of a high 
prevalence of hepatitis, HIV and other perinatal infections. 
Artificial rupture of membranes, therefore, was generally used 
only if additional augmentation was considered necessary or 
delivery was imminent. Continuous fetal heart rate monitoring 
was not possible in all low-risk women, because of the 
shortage of cardiotocograph machines and personnel. In most 
cases intermittent electronic monitoring was used. The 
cardiotocograph tracings were analysed by one of the authors 
(BBM), blinded to the treatment, for uterine contraction and 
fetal heart rate abnormalities, and entered separately onto the 
database. 
The sample size calculation was based on the incidence of 
the primary outcome, failed vaginal delivery within 24 hours, 
of 58% in randomised trials of vaginal misoprostol versus 
dinoprostone.11 To detect a reduction to 40% with 95% certainty 
and 90% power required 171 women in each group. 
Data were entered into the Epi-info 6 statistical package and 
analysed independently by one of the authors (JL). Differences 
between groups were expressed as relative risks with 95% 
confidence intervals (Cis). Prespecified subgroups for analysis 
were by cervical status. 
Results 
The baseline data are shown in Table I. There were slightly 
more primiparous women in the Foley catheter/misoprostol 
group (44%), compared with the misoprostol group (37%) and 
the dinoprostone group (36%). In all other respects the groups 
were well matched. 
In the Foley catheter group, misoprostol was used in 
addition to the Foley catheter in all but 1 woman. 
The primary outcome, failure to deliver vaginally within 24 
hours, was similar for the three groups (79/174 v. 70/176 v .. 
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Table I. Baseline data expressed as mean values (standard deviation), or proportions(%) 
Foley /misoprostol Titrated oral Dinoprostone 
(N = 174) misoprostol (N = 176) (N = 176) 
Maternal age (yrs) (mean (SD)) 26.7 (6.0) 27.8 (6.5) 27.3 (6.2) 
Gestation (wks) (mean (SD)) 40 (1.9) 39.9 (2.1) 39.7 (2.4) 
Primiparous 76/173 (44%) 65 (37%) 63/174 (36%) 
Cervical score < 7 129 (74%) 132 (75%) 128 (73%) 
Primary indication for IOL: 
Impaired growth 21 (12%) 17 (10%) 22 (13%) 
Post-term 97 (56%) 90 (51%) 96 (55%) 
Hypertension 37 (21%) 48 (27%) 38 (22%) 
Poor obstetric history 10 (6%) 12 (7%) 10 (6%) 
Maternal request (0.69%) 2 (1%) 1 (0.6%) 
Maternal health concerns 2 (1%) 2 (1%) 1 (0.6%) 
Fetal concerns 6 (3%) 4 (2%) 7 (4%) 
Other 0 1 (0.6%) (0.6%) 
IOL ~ induction of labour. 
Table II. Primary* and secondary outcomes expressed as proportions(%). Differences are expressed as relative risk with 95% confidence 
intervals (Cl) 
Foley /misoprostol Titrated oral Dinoprostone 
(N = 174) misoprostol (N = 176) (N= 176) Relative risk (95% CI) 
Combined v. Combined v. 
N % N % N % misoerostol dinoerostone 
No vaginal delivery 79 45 70 40 70 40 1.14 (0.89- 1.46) 1.14 (0.89- 1.46) 
< 24hours* 
Amniotomy 50/168 30 47/174 27 44/165 26 1.10 (0.79 - 1.57) 1.12 (0.79- 1.57) 
Oxytocin augmentation 23 13 11 6 43 24 2.11 (1.06- 4.21) 0.54 (0.34 - 0.86) 
Misoprostol augmentation 20 11 21 12 0 0.96 (0.54- 1.71) 
Any augmentation 38 22 29 16 43 24 1.33 (0.86 - 2.05) 0.89 (0.61 - 1.31) 
Vaginal bleeding 9/168 5 4 2 6/174 3 2.36 (0.74- 7.51) 1.55 (0.57 - 4.27) 
Uterine tachysystole 6/163 4 13/161 8 12/164 7 0.46 (0.18)- 1.17) 0.50 (0.19- 1.31) 
Uterine hypersystole 1/163 1 1/161 1 1/164 0.99 (0.06 - 15.66) 1.01 (0.06- 15.95) 
Hyperstimulation syndrome 6/163 4 7/161 4 8/164 5 0.85 (0.29 - 2.46) 0.75 (0.27- 2.13) 
Fetal heart rate (FHR changes) 8/163 5 7/161 4 8/164 5 1.13 (0.42 - 3.04) 1.01 (0.39 - 2.62) 
Tocolysis 9/164 5.5 7/170 4 7/170 4 1.18 (0.44- 3.19) 1.38 (0.49- 3.90) 
Analgesia (epidural or opioid) 64/172 37 46/175 26 56/175 32 1.42 (1.03 1.94) 1.16 (0.87. 1.55) 
Meconium 17/168 10 13/174 7.5 15/171 8.8 1.35 (0.68- 2.70) 1.15 (0.6 - 2.23) 
Caesarean section* 36 21 24 14 43 24 1.52 (0.95 - 2.43) 0.85 (0.57 - 1.25) 
Instrumental delivery 4 2 5 3 4 2 0.81 (0.22 - 2.96) 1.01 (0.26- 3.98) 
(vacuum or outlet forceps) 
Indication for caesarean or 
instrument delivery 
Delay 25/173 14 14/175 8 23/172 13 1.81 (0.97- 3.36) 1.08 (0.64- 1.83) 
Fetal distress 13/173 8 13/175 7 17/172 10 1.01 (0.48- 2.12) 0.76 (0.38 - 1.52) 
Other 2/173 2/175 1 3/172 2 1.01 (0.14 -7.10) 0.66 (0.11- 3.92) 
1m 
70/176 respectively) (Table II). Overall augmentation, Analgesia was used more frequently in the Foley 
caesarean section and instrumental delivery were somewhat catheter/misoprostol than the misoprostol group (64/172 v. 
more frequent in the Foley/misoprostol group than in the 46/175, relative risk 1.42, 95% CI 1.03- 1.94). 
misoprostol alone group, but the differences were not Side-effects were very similar between the three groups, 
statistically significant. except that diarrhoea was more common in the 
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Table III. Maternal side-effects and complications, expressed as proportions(%). Differences are expressed as relative risk with 95% confidence 
intervals ( Cl) 
Foley I misoprostol Titrated oral Dinoprostone 
(N"' 174) misoErostol (N = 176) (N= 176) Relative risk (95% CI) 
Combined v Combined v. 
N· % N % N % misoErostol dinoErostone 
Blood loss > 500 m1 42/174 24 43/175 25 43/174 25 0.98 (0.58 . 1.64) 0.98 (0.67. 1.41) 
Pyrexia > 38°C 3/172 2 1/174 1 2/175 1 3.03 (0.32- 28.99) 1.53 (0.26 - 9.02) 
Retained placenta 1/172 1 1/174 1 0 1.01 (0.06- 16.04) 
Other 6/172 3 5/174 3 7/175 4 1.20 (0.37 - 3.86) 0.86 (0.30. 2.51) 
Nausea 31/149 21 23/151 15 19/151 12 1.37 (0.84 - 2.23) 1.65 (0.98 - 2.79) 
Diarrhoea 20/148 14 6/150 4 6/165 4 3.38 (1.4- 8.17) 3.72 (1.53- 9.0) 
Shivering 57/149 38 69/150 46 66/164 41 0.83 (0.64 - 1.09) 0.95 (0.72- 1.25) 
Any side-effect 86/149 58 82/151 54 82/165 50 1.06 (0.87 - 1.30) 1.02 (0.84 - 1.24) 
Table IV. Neonatal outcomes and complications expressed as proportions(%) or mean values (standard deviation, SD). Differences between 
proportions are expressed as relative risk with 95% confidence intervals (Cl) 
Relative risk (95% CO 
Foley I misoprostol Titrated oral Dinoprostone Combined v. Combined v. 
(N = 174) miSO£rOstol (N = 176) (N = 176) misoErostol dinoErostone 
Birth weight (g) (mean (SD)) 3066 (518) 3129 
Missing data 1 0 
5 min Apgar< 7 6/171 (3%) 6/173 
NeonatallCU admission 2/171 (1%) 3/174 
Perinatal death 1/171 (0.6%) 0 
Neonatal seizures 1/170 (0.6%) 1/173 
Neonatal sepsis 1/171 (0.6% 0 
Other 6/171 (4%) 6/173 
Foley I misoprostol group (Table III). There were no cases of 
uterine rupture or sepsis. 
Neonatal complications were also very similar (Table IV), 
although the event rates were too low for meaningful statistical 
comparison. 
Discussion 
In terms of inducing labour contractions, Foley catheter 
insertion was l.ess successful than has been reported previously. 
In all but 1 case, misoprostol was required to induce labour 
contractions. Neither did preliminary 'ripening' of the cervix 
with the Foley catheter produce measurable benefits in terms 
of shorter labour or fewer complications, although the numbers 
studied were too small to exclude the possibility "of a reduction 
in infrequent events such as uterine tachysystole. 
This study provides no evidence of an advantage to using 
the Foley catheter method followed when necessary by 
misoprostol induction in women with intact membranes, 
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(3%) 9/175 (5%) 1.01 (0.33 - 3.08) 0.67 (0.24 -1.84) 
(2%) 3/175 (2%) 0.68 (0.11 • 4.01) 0.68 (0.12- 4.03) 
1/174 (0.6%) 1.02 (0.06 - 16.1) 
{0.6%) 0 1.02 (0.06. 16.0) 
0 
(3%) 4/174 (2%) 1.01 (0.33 . 3.08) 1.53 (0.44. 5.31) 
particularly as this adds expense to the procedure, and is 
uncomfortable for the woman. However, the fact that failure to 
deliver within 24 hours of randomisation was similar across 
groups does suggest that the Foley catheter had an influence 
on the process of labour induction. Misoprostol was used only 
after expulsion or removal (at 24 hours) of the Foley catheter, 
and greatly increased randomisation to delivery times would 
be expected had the Foley catheter been ineffective. 
The cardiotocographic data may underestimate 
complications as electronic monitoring was intermittent in 
some cases. As this limitation applied to all three groups, the 
data are presented for comparative purposes. 
Further research should focus on the use of the Foley 
catheter technique in situations in which prostaglandin 
preparations are not available, or contraindicated. A particular 
problem is induction of labour in women with previous 
caesarean section/'·" in whom use of prostaglandin 
preparations, particularly misoprostol, may be hazardous. 
Although this problem was not addressed directly in this 
ORIGINAL ARTICLES 
study, the results suggest that Foley catheter placement alone is 
unlikely to be adequate. Additional procedures such as extra-
amniotic saline infusion, or artificial rupture of membranes 
after expulsion of the catheter, are worth investigating in these 
circumstances. 
Conclusions 
Use of extra-amniotic Foley catheter placement followed when 
necessary by titrated oral misoprostol solution for induction of 
labour showed no measurable benefits over the use of oral 
misoprostol alone, or vaginal dinoprostone. 
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Liverpool, for advice. 
References 
1. Thiery M, Baines CJ, Keirse MJNC. The development of methods for inducing labour. In: 
Chalmers I, Enkin MW, Keirse MJNC, eds. Effective Care in Pregnancy and Childbirth. Oxford: 
Oxford University Press, 1989: 971. 
May 2003, Vol. 93, No.5 SAMJ 
2. Sciscione AC, Nguyen L, Manley J, Pollock M, Maas B, Colmorgen G. A randomised 
comparison of transcervical Foley catheter to intravaginal misoprostol for preinduction 
cervical ripening. Obstet Gyneco/2001; 97: 603~607. 
3. A tad J, Hallak M, Auslender R, Porat~Packer T, Zarfati D, Abramovici H. A randomised 
comparison of prostaglandin E2, oxytocin, and the double-balloon device in inducing labor. 
Obstet Gynecol1996; 87; 223-227. 
4. Buccellato CA, Stika CS, Frederiksen MC. A randomised trial of misoprostol versus extra-
amniotic sodium chloride infusion with oxytocin for induction of labor. Am J Obstet Gynecol 
2000; 182: 1039-1044. 
5. Boulvain M, Kelly A, Lohse C, Stan C, Irion 0. Mechanical methods for induction of labour 
(Cochrane Review). In: The Cochrane Libr:ary, Issue 2, 2002. Oxford: Update Software. 
6. Rust 0, Greybush M, Atlas R, Balducci J. Does combination pharmacologic and mechanical 
pre-induction cervical ripening improve ripening to delivery interval? Am J Obstet Gynecol 
2000; 182: SI36. 
7. Goldberg AB, Greenberg MB, Darney PD. Misoprostol and pregnancy. N Engl J Med 2001; 
344:38-47. 
8. Hofmeyr GJ. Induction of·labour with rnisoprostol. Curr Opin Obstet Gynecol2001; 13: 577-
581. 
9. Hofmeyr GJ, Gulmezoglu AM, Alfirevic Z. Misoprostol for induction of labour: a systematic 
review. Br J Obstet Gynecol 1999; 106:798-803. 
10. Alfirevic Z, Howarth G, Gausmann A Oral misoprostol for induction of labour with a viable 
fetus (Cochrane Review). In: The Cochrane Library, Issue 2, 2002. Oxford: Update Software. 
11. Hofmeyr GJ, Gulmezoglu AM. Vaginal misoprostol for cervical ripening and labour 
induction in late pregnancy (Cochrane review). In: The Cochrane Library, Issue 2, 2002. 
Oxford: Update Software. 
12. Mathews JE, Mathai M, George A Uterine rupture in a multiparous woman during labor 
induction with oral misoprostol. Int J Gynaecol Obstet 2000; 68: 43-44. 
13. Hofmeyr GJ, Matonhodze BB, Alfirevic Z, Campbell E, de Jager M, Nikodem C. Titrated oral 
misoprostol solution: a new method of labour induction. S Afr Med] 2001; 91: 775-776. 
14. Hofmeyr GJ, Alfirevic Z, Matonhodze BB, Brocklehurst P, Campbell E, Nikodem VC. Titrated 
oral misoprostol solution for labour induction: A multi-centre, randomised trial. Br J Obstet 
Gynoecol 2001; 108: 952-959. 
15. Bishop EH. Pelvic scoring for elective induction. Obstet Gynecoll964; 24:266-268. 
16. Gherman RB, Heath T. Trial of labor after cesarean delivery: a pilot study of oral misoprostol 
for preinduction cervical ripening. Obstet Gynecol 2001; 97: Suppl1, 568. 
17. Hill DA, Chez RA, Quinlan J, Fuentes A, LaCombe J. Uterine rupture and dehiscence 
associated with intravaginal misoprostol cervical ripening. J Reprod Med 2000; 45: 823-826. 
